Alpha-Helical Peptide Disrupts Tumor Vesicles for Immunotherapy

Solution Overview

Problem

Current cancer immunotherapies using immune checkpoint inhibitors have limited efficacy due to tumor-derived vesicles that create an immunosuppressive tumor microenvironment, neutralizing antibodies and inhibiting T-cell action, necessitating a strategy to disrupt these vesicles to enhance treatment sensitivity and effectiveness.

Innovation Solution

A peptide with an α-helix structure, specifically designed to disrupt tumor-derived vesicles, is developed, which can be administered with an immune checkpoint inhibitor to inhibit T-cell functional impairment and control the tumor microenvironment, potentially improving cancer immunotherapy outcomes by enhancing T-cell activity and inhibiting metastasis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint inhibitors are administered to treat cancer, then T-cell activation is enhanced, but tumor-derived vesicles neutralize the antibodies and inhibit T-cell action, reducing treatment effectiveness

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by using the tumor-derived vesicles themselves as delivery vehicles. The vesicles, which normally neutralize antibodies and inhibit T-cell action, are repurposed to deliver immune checkpoint inhibitor antibodies directly to the tumor microenvironment. This converts the harmful vesicles into beneficial delivery systems, allowing the antibodies to reach their target despite the presence of vesicles.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent uses tumor-derived vesicles as an intermediary carrier between the administered antibodies and the tumor cells. Instead of antibodies directly interacting with tumor cells in the presence of neutralizing vesicles, the vesicles themselves become the intermediary that transports the antibodies into the tumor microenvironment, facilitating drug delivery while evading immune clearance.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If tumor-derived vesicles are present in the bloodstream, then they create an immunosuppressive tumor microenvironment, but removing or inhibiting these vesicles is necessary to increase response rate to immune checkpoint inhibitors

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Rather than attempting to remove or destroy tumor-derived vesicles, the patent converts them into beneficial delivery vehicles. The vesicles that create an immunosuppressive environment are repurposed to deliver immune-activating antibodies directly to the tumor site, transforming the harmful immunosuppressive agents into tools for enhancing immune response.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the functional parameter of tumor-derived vesicles from immunosuppressive agents to immunotherapeutic delivery vehicles. By modifying how the vesicles are utilized rather than removing them, the treatment response rate is increased while avoiding the need for complex vesicle removal strategies.

Inventive Principle:
Principle #35Parameter changes

3Adaptability or versatility

If conventional chemotherapy is used to treat cancer, then it can treat patients who cannot undergo surgery or radiation, but drug resistance and recurrence occur due to the tumor microenvironment

Engineering Contradiction:
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent replaces conventional chemotherapy's non-specific cytotoxic mechanism with an immune-mediated mechanism. Instead of using chemicals to kill cancer cells directly (which leads to resistance), the system uses immune checkpoint inhibitors delivered via tumor-derived vesicles to activate T-cells to selectively target and destroy cancer cells, providing a more sustainable long-term outcome.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces T-cells as intermediary effectors between the administered antibodies and cancer cells. Rather than chemotherapy drugs directly attacking cancer cells (leading to resistance), the antibodies activate T-cells which then serve as living intermediaries to recognize and eliminate cancer cells, reducing drug resistance and recurrence.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide effectively disrupts tumor-derived vesicles, enhancing the sensitivity of cancer immunotherapy and inhibiting cancer metastasis by improving T-cell function and reducing the immunosuppressive tumor microenvironment, as demonstrated by its ability to decrease PD-L1 expression on exosomes and increase T-cell proliferation and infiltration into tumors.

Implementation Method 1

a peptide that has an α-helix structure capable of controlling the tumor microenvironment and inhibiting T cell functional impairment by disrupting tumor-derived vesicles

Methodology Applied
Scientific Effectα-helix structure interaction:

Data Source

PatentUS20230113262A1Peptide for cancer immunotherapy rupturing tumor-derived vesicle and use thereof
Publication Date: 2023.04.13
  • US20230113262A1 patent drawing
  • US20230113262A1 patent drawing
  • US20230113262A1 patent drawing

AI summary

The present invention relates to a peptide for cancer immunotherapy that disrupts tumor-derived vesicles and a use thereof. The peptide according to the present invention has an α-helical structure, inhibits T-cell functional impairment caused by tumor-derived vesicles and controls the formation of a tumor microenvironment as an immunosuppressive environment by disrupting the tumor-derived vesicles, and has effects of not only enhancing cancer immunotherapy activity but also inhibiting the metastasis of cancer cells through co-administration with an immune checkpoint inhibitor. Additionally, when the peptide is modified with PEG through a pH-sensitive linker, it has effects of increasing the stability of the peptide in vivo, and disrupting tumor-derived vesicles under the pH condition of the tumor microenvironment. Accordingly, the peptide of the present invention is expected to be effectively used in a composition for cancer immunotherapy, a composition for enhancing the sensitivity of cancer immunotherapy, or the composition for inhibiting cancer metastasis.